reports
- Tushar Manudhane
MOSL: SOLARA ACTIVE PHARMA (Buy)- Comprehensive approach in API/CRAMS ...
SOLARA ACTIVE PHARMA: Comprehensive approach in API/CRAMS to drive growth (SOLARA IN, Mkt Cap USD0.8b, CMP INR1728, TP INR2050, 20% Upside, Buy) Customer additions/differentiated technology aids better visibility in the CRAMS business SOLARA delivered an in line 1QFY22 earnings, led by increased contribution from new products, ramp in other markets like Asia-Pacific, and healthy growth in the Contract Research and Manufacturing Services (CRAMS) business. SOLARA has delivered a robust per...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.